{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:21:54Z","timestamp":1779168114654,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81403020"],"award-info":[{"award-number":["81403020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273547"],"award-info":[{"award-number":["81273547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91529304"],"award-info":[{"award-number":["91529304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473230"],"award-info":[{"award-number":["81473230"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673468"],"award-info":[{"award-number":["81673468"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81502407"],"award-info":[{"award-number":["81502407"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["111-2-07"],"award-info":[{"award-number":["111-2-07"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK2014666"],"award-info":[{"award-number":["BK2014666"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejphar.2017.06.001","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T18:00:44Z","timestamp":1496772044000},"page":"117-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia"],"prefix":"10.1016","volume":"811","author":[{"given":"Duowei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiani","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.06.001_bib1","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1038\/srep06948","article-title":"Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study","volume":"4","author":"Banavath","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2017.06.001_bib2","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ccr.2011.03.003","article-title":"Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036","volume":"19","author":"Chan","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2017.06.001_bib3","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2017.06.001_bib4","doi-asserted-by":"crossref","first-page":"29559","DOI":"10.1038\/srep29559","article-title":"Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib","volume":"6","author":"Dessilly","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2017.06.001_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2017.06.001_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2017.06.001_bib7","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/leu.2016.220","article-title":"Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer","volume":"30","author":"Geissler","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2017.06.001_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.stem.2012.02.017","article-title":"Genetic and pharmacologic inhibition of beta-catenin targets imatinib-resistant leukemia stem cells in CML","volume":"10","author":"Heidel","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejphar.2017.06.001_bib9","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2017.06.001_bib10","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2017.06.001_bib11","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2017.06.001_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2017.06.001_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","article-title":"IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development","volume":"20","author":"Reynaud","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2017.06.001_bib14","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1084\/jem.20130706","article-title":"Cross talk between Wnt\/beta-catenin and Irf8 in leukemia progression and drug resistance","volume":"210","author":"Scheller","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2017.06.001_bib15","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2017.06.001_bib16","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/bph.12183","article-title":"Targeting survival pathways in chronic myeloid leukaemia stem cells","volume":"169","author":"Sinclair","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.06.001_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","article-title":"Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence","volume":"23","author":"Takeishi","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2017.06.001_bib18","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.18632\/oncotarget.3665","article-title":"Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2017.06.001_bib19","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2015-09-666214","article-title":"The impact of multiple low-level BCR-ABL1mutations on response to ponatinib","volume":"127","author":"Parker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2017.06.001_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1080\/14737159.2016.1227243","article-title":"Molecular monitoring of chronic myeloid leukemia: present and future","volume":"16","author":"Yeung","year":"2016","journal-title":"Expert Rev. Mol. Diagn."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917303965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917303965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:21:51Z","timestamp":1757974911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917303965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"alternative-id":["S0014299917303965"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.001","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}